|Dr. John K. A. Prendergast Ph.D.||Co-Founder & Non-Exec. Chairman||95k||N/A||63|
|Dr. Carl Spana Ph.D.||Co-Founder, Pres, CEO & Director||947.65k||N/A||55|
|Mr. Stephen T. Wills CPA, MST||CFO, COO, Principal Accounting Officer, executive VP, Treasurer & Sec.||886.45k||N/A||60|
|Burns McClellan||VP of Investor Relations||N/A||N/A||N/A|
|Dr. Johna Lucas M.A., M.D., F.A.C.O.G.||Chief Medical Officer||N/A||N/A||N/A|
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The companys principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Palatin Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.